Psychiatry · SSRIRegulatory Approvalregulatorymid-term

FDA Approves ANDA220768 for Fluvoxamine Maleate by Micro Labs

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:05:02 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of ANDA220768 for Fluvoxamine Maleate by Micro Labs introduces a new competitor in the SSRI market. This could impact pricing and market share for existing products, necessitating strategic adjustments from current market players. Regulatory context from FDA (FDA AP — FLUVOXAMINE MALEATE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for similar products. The strongest clinical anchor is Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene (ClinicalTrials.gov), moderate corpus alignment. In Psychiatry · SSRI, 5 regulatory and 5 competitive items passed relevance filtering for Micro Labs.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FLUVOXAMINE MALEATE (ORIG) (FDA). Entity match (micro labs); Regulatory pathway relevance (nda). The approval signifies a shift in the regulatory landscape for SSRIs, which may prompt existing companies to reassess their compliance and approval strategies.

Key Risks

Elevated medium regulatory exposure for Micro Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Micro Labs could lead to price competition, affecting revenue streams for existing SSRI products and altering market dynamics.
First approval of PD‑1 inhibitors in combination with Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S.
Upside for Micro Labs may improve if Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for similar products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent pricing strategies from Micro Labs.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FLUVOXAMINE MALEATE (ORIG)
FDAhigh relevance
Entity match (micro labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FLUVOXAMINE MALEATE (ORIG)
FDAhigh relevance
Entity match (fluvoxamine maleate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Endocarditis Clinical Awareness, Research, and Evaluation in Sweden
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of Adverse Effects Related to Prescribed Medications in Periodontology Clinic
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History Study of CADASIL
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Tryngolza for Reducing Acute Pancreatitis Risk in Severe Hypertriglyceridemia
Humanexa Signalsmedium relevance
Moderate corpus alignment

Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Micro Labs
Fluvoxamine Maleate

Commercial impact

medium

The entry of Micro Labs could lead to price competition, affecting revenue streams for existing SSRI products and altering market dynamics.

Regulatory impact

medium

The approval signifies a shift in the regulatory landscape for SSRIs, which may prompt existing companies to reassess their compliance and approval strategies.

What to watch

Monitor market entry timelines and any subsequent pricing strategies from Micro Labs.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.